<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0109211000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Veklury
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        REMDESIVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1769.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GILEAD SCIENCES LIMITED (CORK)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GILEAD SCIENCES LIMITED (CORK)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gilead Sciences Ireland UC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Veklury is remdesivir. It is an antiviral medicine used for treating COVID‑19.</p><p>COVID‑19 is caused by a virus called a coronavirus. Veklury stops the virus multiplying in cells and this stops the virus multiplying in the body. This can help your body to overcome the virus infection and may help you get better faster.</p><p>Veklury will be given to treat COVID‑19 in:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults and children ( at least 4 weeks old and weighing at least 3&nbsp;kg ) who have pneumonia, and need extra oxygen to help them breathe, but who are not on artificial ventilation (where mechanical means are used to assist or replace spontaneous breathing at start of treatment).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adults and children (weighing at least 40&nbsp;kg) &nbsp;who do not need extra oxygen to help them breathe and are at increased risk for progressing to severe COVID-19.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You will not usually be given Veklury:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic</strong> to remdesivir, or any of the other ingredients of this medicine (listed in section&nbsp;6)</p><p><strong>Talk to your doctor or nurse as soon as possible,</strong> if this applies to you.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or nurse before starting on Veklury:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have liver problems.</strong> Some people develop increased liver enzymes when given Veklury. Your doctor will do blood tests before starting treatment to check whether you can be given it safely.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have kidney problems.</strong> Some people with severe kidney problems may not be given this medicine. Your doctor will do blood tests to check whether you can be given it safely.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are immunocompromised.</strong> Your doctor may monitor you more closely if your immune system is not working properly to ensure the treatment is working.</p><p>&nbsp;</p><p><strong>Reactions following the infusion</strong></p><p>Veklury can cause allergic reactions following and during the infusion, including anaphylactic reactions (sudden life-threatening allergic reactions). Allergic reactions have been seen rarely. For anaphylactic reactions frequency cannot be estimated from the available data.</p><p>Symptoms can include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes to blood pressure or heart rate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low oxygen level in blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High temperature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, wheezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue or throat (angioedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shivering.</p><p><strong>Tell your doctor or nurse straight away</strong> if you notice any of these effects.</p><p>&nbsp;</p><p><strong>Blood tests before and during treatment</strong></p><p>If you are prescribed Veklury, you will be given blood tests before treatment starts. Patients being treated with Veklury will have blood tests during their treatment as determined by their health care professional. These tests are to check for kidney or liver problems, and how quickly you blood clots. Veklury will be stopped if your kidney or liver show signs of damage during treatment. See section 4 <em>(</em><em>Possible side effects)</em>.</p><p><strong>Children and adolescents</strong></p><p>Veklury is not to be given to children under 4 weeks old or to children who weigh less than 3&nbsp;kg. Not enough is known for it to be given to these children.</p><p><strong>Other medicines and Veklury</strong></p><p><strong>Tell your doctor or nurse</strong> about any other medicines you are taking, or have recently taken.</p><p>Do not take chloroquine or hydroxychloroquine at the same time as Veklury.</p><p>Certain medicines e.g. midazolam or pitavastatin should be taken at least 2&nbsp;hours after Veklury as Veklury can affect the way they work.</p><p>Veklury can affect the way certain medicines (e.g. theophylline or midazolam) work.</p><p>Certain medicines (e.g. rifampicin) can affect the way Veklury works.</p><p><strong>Tell your doctor if you are taking any of these medicines</strong></p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Tell your doctor or nurse if you are pregnant,</strong> or if you might be. There is not enough information to be sure that Veklury is safe for use in pregnancy. Veklury will only be given if the potential benefits of treatment outweigh the potential risks to the mother and the unborn child. <strong>You must use effective contraception while having Veklury treatment.</strong></p><p><strong>Tell your doctor or nurse if you are breast-feeding.</strong> It is not yet known whether Veklury or the COVID‑19 virus pass into human breast milk, or what the effects might be on the baby or milk production. Your doctor will help you decide whether to continue breast-feeding or to start treatment with Veklury. You will need to consider the potential benefits of treatment for you, compared with the health benefits and risks of breast-feeding for your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Veklury is not expected to have any effect on your ability to drive.</p><p>&nbsp;</p><p><strong>Veklury contains a cyclodextrin</strong></p><p>This medicine contains 3&nbsp;g betadex sulfobutyl ether sodium in each 100&nbsp;mg dose of Veklury (6&nbsp;g in the starting dose). This ingredient is a <em>cyclodextrin emulsifier</em> that helps the medicine to disperse in the body.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Veklury will be given to you by a nurse or doctor, as a drip into a vein (an <em>intravenous infusion</em>) lasting 30 to 120&nbsp;minutes, once a day. You will be closely monitored during your treatment.</p><p><strong>Recommended dose for adults and children:</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Adults</strong></p></td><td style="vertical-align:top"><p><strong>Children (weighing at least 40&nbsp;kg)</strong></p></td><td style="vertical-align:top"><p><strong>Children at least 4&nbsp;weeks old (weighing at least 3&nbsp;kg but less than 40&nbsp;kg)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Day 1</strong></p><p>(single starting dose)</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td><td style="vertical-align:top"><p>5&nbsp;mg per kg&nbsp;of body weight</p></td></tr><tr><td style="vertical-align:top"><p><strong>Day 2 and onwards</strong></p><p>(once daily)</p></td><td style="vertical-align:top"><p>100&nbsp;mg</p></td><td style="vertical-align:top"><p>100&nbsp;mg</p></td><td style="vertical-align:top"><p>2.5&nbsp;mg per kg of body weight</p></td></tr></tbody></table><p><strong>How long treatment lasts</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><thead><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><strong>Adults</strong></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><strong>Children (weighing at least 40&nbsp;kg)</strong></p></td><td style="vertical-align:top"><p><strong>Children at least 4&nbsp;weeks old (weighing at least 3&nbsp;kg but less than 40&nbsp;kg)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Patients who have<strong> pneumonia and need extra oxygen</strong></p></td><td style="vertical-align:top"><p>Daily<strong> </strong>for<strong> at least 5&nbsp;days. </strong>May be extended up to a <strong>total of 10&nbsp;days</strong>.</p></td><td style="vertical-align:top"><p>Daily<strong> </strong>for<strong> at least 5&nbsp;days. </strong>May be extended up to a <strong>total of 10&nbsp;days</strong>.</p></td><td style="vertical-align:top"><p>Daily for up to a<strong> total of</strong> <strong>10&nbsp;days</strong>.</p></td></tr><tr><td style="vertical-align:top"><p>Patients<strong> </strong>who<strong> do not need extra oxygen </strong>and are at increased risk for progressing to severe COVID-19</p></td><td style="vertical-align:top"><p>Daily for 3<strong>&nbsp;days</strong>, starting within 7&nbsp;days of the onset of COVID-19 symptoms.</p></td><td style="vertical-align:top"><p>Daily for <strong>3&nbsp;days</strong>, starting within 7&nbsp;days of the onset of COVID-19 symptoms.</p></td><td style="vertical-align:top"><p>Not applicable.</p></td></tr></tbody></table><p>See the <em>Instructions for healthcare professionals</em> which gives details on how the Veklury infusion is given.</p><p><strong>If you are given more or less Veklury than you should</strong></p><p>As Veklury is only given to you by a healthcare professional, it is unlikely that you will be given too much or too little. If you have been given an extra dose, or missed one, <strong>tell your nurse or doctor straight away.</strong></p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Some side effects could be or could become serious:</p><p><strong>Rare</strong></p><p>(these may affect up to 1 in 1000 patients)</p><ul><li>Allergic reactions following and during the infusion. Symptoms can include:</li></ul><ul><li><ul><li>Changes to blood pressure or heart rate</li><li>Low oxygen level in blood</li><li>High temperature</li><li>Shortness of breath, wheezing</li><li>Swelling of the face, lips, tongue or throat (angioedema)</li><li>Rash</li><li>Feeling sick (nausea)</li><li>Being sick (vomiting)</li><li>Sweating</li><li>Shivering</li></ul></li></ul><p><strong>Uncommon</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness at the injection site.</p><p><strong>Not known</strong></p><p>(frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic reactions, anaphylactic shock (sudden life-threatening allergic reactions)</p><p>Symptoms are the same as for allergic reactions however the reaction is more severe and requires immediate medical care.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus bradycardia (heart beats more slowly than normal).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine may leak from the vein or be accidentally injected into the tissue surrounding the vein.</p><p><strong>Tell your doctor or nurse straight away if you notice any of these effects.</strong></p><p>&nbsp;</p><p><strong>Other side effects:</strong></p><p><strong>Very common side effects</strong></p><p>(these may affect more than 1 in 10 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood tests may show an increase in liver enzymes, called<em> transaminases</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood tests may show it takes longer for blood to clot</p><p><strong>Common side effects</strong></p><p>(these may affect up to 1 in 10 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. &nbsp;</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Before use,</strong> this medicinal product should be stored below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Once reconstituted,</strong> Veklury should be diluted immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Once diluted,</strong> Veklury should be used immediately. If necessary, bags of diluted solution can be stored for up to 24&nbsp;hours at room temperature (20&deg;C to 25&deg;C), or for up to 48&nbsp;hours in a refrigerator (2&deg;C to 8&deg;C). Do not allow more than 48&nbsp;hours between dilution and administration.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The active substance</strong> is remdesivir. Each vial contains 100&nbsp;mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The other ingredients</strong> are: betadex sulfobutyl ether sodium, hydrochloric acid and sodium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Veklury 100 mg powder for concentrate for solution for infusion is a white, off-white to yellow powder, to be reconstituted and then diluted into sodium chloride solution prior to administration by intravenous infusion. It is supplied in a single-use clear glass vial.

Veklury is available in cartons containing 1 vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gilead Sciences Ireland UC</p><p>Carrigtohill</p><p>County Cork, T45&nbsp;DP77</p><p>Ireland</p><p>Bulk manufacturing sites:</p><p>Jubilant&nbsp;HollisterStier, LLC&nbsp;<br />3525 N. Regal Street&nbsp;<br />Spokane, WA 99207&nbsp;<br />USA</p><p>or</p><p>Patheon&nbsp;Manufacturing Services LLC&nbsp;<br />5900 Martin Luther King Jr Highway&nbsp;<br />Greenville, NC 27834&nbsp;<br />USA&nbsp;<br />or</p><p>Hikma&nbsp;Farmaceutica&nbsp;(Portugal) S.A.&nbsp;<br />Estrada Rio Da Mo, 8/8A/8B&nbsp;<br />Terrugem&nbsp;SNT, 2705-906&nbsp;<br />Portugal&nbsp;</p><p>or</p><p>Patheon&nbsp;Italia S.p.A.&nbsp;&nbsp;<br />Viale&nbsp;Gian&nbsp;Battista&nbsp;Stucchi&nbsp;110&nbsp;<br />Monza, 20900&nbsp;<br />Italy&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في فيكلوري هي ريمديسيفير. وهي دواء مضاد للفيروسات يُستخدَم في علاج كوفيد-19.</p><p>&nbsp;</p><p dir="RTL">وينجمُ كوفيد-19 عن فيروس اسمه فيروس كورونا. دواء فيكلوري يوقف تضاعُف الفيروس داخل الخلايا، مما يوقف تضاعُف الفيروس في الجسم. ويمكن لهذا أن يساعد جسمك في التغلب على العدوى الفيروسية وقد يساعدك في التحسن في وقتٍ أسرع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعطى فيكلوري لعلاج كوفيد-19 لدى:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغين والأطفال (بعمر 4 أسابيع على الأقل ممَّن يبلغ وزنهم 3 كجم على الأقل) المصابين بالتهاب رئوي، ويحتاجون إلى أكسجين إضافي لمساعدتهم في التنفس، على ألا يكونوا موضوعين على التهوية الاصطناعية (التي تُستخدَم فيها وسائل ميكانيكية لمساعدة المريض على التنفس الطبيعي أو استعاضته في بداية العلاج).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغين والأطفال (ممِّن يبلغ وزنهم 40 كجم على الأقل) الذين لا يحتاجون إلى أكسجين إضافي لمساعدتهم على التنفس وعرضة لخطر متزايد من الإصابة بأعراض كوفيد-19 الشديدة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لن تُعطى فيكلوري عادةً:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت لديك حساسية</strong> تجاه مادة ريمديسيفير، أو تجاه أيٍّ من المكونات الأخرى في هذا الدواء (وهي مذكورة في الفقرة 6)</p><p dir="RTL"><strong>تحدث مع طبيبك أو ممرضك في أقرب وقتٍ ممكن،</strong> إذا كانت هذه الحالة تنطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">قبل بدء العلاج بفيكلوري، تحدث مع طبيبك أو ممرضك:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت لديك مشاكل في الكبد.</strong> يرتفع لدى بعض الأشخاص مستوى إنزيمات الكبد عند إعطائهم فيكلوري. وسيطلب طبيبك إجراء اختبارات دموية قبل بدء العلاج للتحقق مما إذا كان يمكن إعطاؤه لك بأمان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت لديك مشاكل في الكليتين.</strong> قد لا يُعطى هذا الدواء لبعض الأشخاص الذين يعانون من مشاكل وخيمة في الكليتين. سيطلب طبيبك إجراء اختبارات دموية للتحقق مما إذا كان يمكن إعطاؤه لك بأمان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك قصور في المناعة. قد يراقبك طبيبك عن كثب إذا كان الجهاز المناعي لديك لا يعمل بشكل ملائم لضمان نجاح العلاج</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التفاعلات التالية للتسريب</strong></p><p dir="RTL">قد يسبب فيكلوري تفاعلات أرجية أثناء التسريب وبعده، بما في ذلك التفاعلات التأقية (تفاعلات أرجية مفاجئة مهددة للحياة). لوحظ حدوث التفاعلات الأرجية نادراً. وبالنسبة للتفاعلات التأقية، فلا يمكن تقدير معدل حدوثها من البيانات المتاحة.</p><p dir="RTL">يمكن أن تشتمل الأعراض على:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في ضغط الدم أو سرعة القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الأكسجين في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، وَزيز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم في الوجه أو الشفتين أو اللسان أو الحلق (وذمة وعائية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رغبة في التقيُّؤ (غثيان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استفراغ (قيء)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرُّق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاد (قشعريرة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو ممرِّضك فوراً </strong>إذا لاحظت أياً من هذه التأثيرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاختبارات الدموية قبل العلاج وأثناءه</strong></p><p dir="RTL">إذا وُصِف لك فيكلوري، فستُجرى لك اختبارات دموية قبل بدء العلاج. تُجرى للمرضى الذين يخضعون للعلاج بفيكلوري اختبارات دموية أثناء فترة العلاج، وفقاً لما يحدِّده العامل في الرعاية الصحية. والهدف من هذه الاختبارات هو التحقق من وجود مشاكل في الكليتين أو الكبد ومن سرعة تجلط الدم لديك. سيُوقَف العلاج بفيكلوري إذا ظهرت علاماتٌ تدلُّ على تعرض كليتيك أو كبدك للأذى خلال فترة العلاج. راجع الفقرة 4 <em>(التأثيرات الجانبية المحتملة)</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب ألا يُعطى فيكلوري للأطفال الذين تقلُّ أعمارهم عن 4 أسابيع أو يقلُّ وزنهم عن 3 كجم. لم يُعرَف عن الدواء ما يكفي من معلومات لإعطائه لهؤلاء الأطفال.</p><p dir="RTL"><strong>الأدوية الأخرى وفيكلوري</strong></p><p dir="RTL"><strong>أخبر طبيبك أو ممرضك</strong> بشأن أي أدوية أخرى تأخذها حالياً، أو أخذتَها مؤخراً.</p><p dir="RTL">لا تأخذ كلوروكين أو هيدروكسي كلوروكين مع فيكلوري في الوقت نفسه.</p><p dir="RTL">يجب عدم أخذ أدوية معينة، مثل ميدازولام أو بيتافاستاتين، إلا بعد تلقي فيكلوري بساعتين على الأقل، لأن فيكلوري قد يؤثر على طريقة عملها.</p><p dir="RTL">قد يؤثر فيكلوري على طريقة عمل أدوية معينة (مثل ثيوفيللين أو ميدازولام).</p><p dir="RTL">قد تؤثر أدوية معينة (مثل ريفامبيسين) على طريقة عمل فيكلوري.</p><p dir="RTL"><strong>أخبر طبيبك إذا كنت تأخذ أياً من هذه الأدوية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL"><strong>أخبري طبيبك أو ممرضك إذا كنت حاملاً،</strong> أو إذا كان من المحتمل أن تكوني حاملاً. لا تتوفر معلوماتٌ كافيةٌ للتأكد من أن استخدام فيكلوري آمنٌ أثناء الحمل. لن يُعطى فيكلوري إلا إذا كانت المنافع المحتملة للعلاج تفوق المخاطر المحتملة على الأم والجنين. <strong>يجب أن تستعملي وسيلةً فعالةً لمنع الحمل خلال فترة العلاج بفيكلوري.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبري طبيبك أو ممرضك إذا كنت ترضعين طفلك من الثدي.</strong> لم يُعرَف بعدُ ما إذا كان فيكلوري أو فيروس كوفيد-19 يصلُ إلى حليب الثدي البشري، كما لم تُعرَف بعد التأثيرات المحتملة على الطفل أو على إفراز الحليب. سيساعدك طبيبك في اتخاذ قرار متابعة إرضاع طفلك من الثدي أو بدء العلاج بفيكلوري. سيوجب عليك التفكير في المنافع المحتملة للعلاج بالنسبة إليك، بالمقارنة مع المنافع والمخاطر الصحية للإرضاع من الثدي على طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">لا يُتوقَّع أن يكون لفيكلوري أي تأثير على قدرتك على القيادة.</p><p dir="RTL"><strong>يحتوي فيكلوري على سايكلودِكسترين</strong></p><p dir="RTL">يحتوي هذا الدواء على 3 جم من بيتادِكس سلفوبوتيل إيثر الصوديوم في كل جرعة قدرُها 100 ملجم من فيكلوري (6 جم في الجرعة البدئية). وهذا المكوِّن هو <em>مادة سايكلودِكسترين مُستحلِبة</em> تساعد في تبعثر الدواء داخل الجسم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يقوم ممرض أو طبيب بإعطائك فيكلوري عن طريق التستيل داخل أحد الأوردة (<em>تسريب وريدي</em>) لمدة 30 إلى 120 دقيقة، مرة واحدة يومياً. ستُراقَب عن كثب خلال علاجك.</p><p dir="RTL"><strong>الجرعة المُوصى بها للبالغين والأطفال:</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأطفال البالغون من العمر 4 أسابيع على الأقل (ممِّن يبلغ وزنهم 3 كجم على الأقل لكن دون 40 كجم)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الأطفال (ممِّن يبلغ وزنهم 40 كجم على الأقل)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>البالغون</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p dir="RTL">5 ملجم لكل كجم من وزن الجسم</p></td><td style="vertical-align:top"><p dir="RTL">200 ملجم</p></td><td style="vertical-align:top"><p dir="RTL">200 ملجم</p></td><td style="vertical-align:top"><p dir="RTL"><strong>اليوم 1</strong></p><p dir="RTL">(جرعة بدئية وحيدة)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">2.5 ملجم لكل كجم من وزن الجسم</p></td><td style="vertical-align:top"><p dir="RTL">100 ملجم</p></td><td style="vertical-align:top"><p dir="RTL">100 ملجم</p></td><td style="vertical-align:top"><p dir="RTL"><strong>اليوم 2 فما بعد</strong></p><p dir="RTL">(مرة واحدة يوميًا)</p></td></tr></tbody></table><p dir="RTL"><strong>إلى متى يستمر العلاج</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأطفال البالغون من العمر 4 أسابيع على الأقل (ممِّن يبلغ وزنهم 3 كجم على الأقل لكن دون 40 كجم)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الأطفال (ممِّن يبلغ وزنهم 40 كجم على الأقل)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>البالغون</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p dir="RTL">يوميًا لما يصل إلى <strong>إجمالي 10 أيام.</strong></p></td><td style="vertical-align:top"><p dir="RTL">يوميًا لمدة 5 أيام على الأقل. قد يتم تمديد العلاج لما يصل إلى <strong>إجمالي 10 أيام.</strong></p></td><td style="vertical-align:top"><p dir="RTL">يوميًا لمدة 5 أيام على الأقل. وقد يتم تمديد العلاج لما يصل إلى <strong>إجمالي 10 أيام.</strong></p></td><td style="vertical-align:top"><p dir="RTL">المرضى المصابون <strong>بالتهاب رئوي، ويحتاجون إلى أكسجين إضافي</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا ينطبق.</p></td><td style="vertical-align:top"><p dir="RTL">يوميًا لمدة 3 أيام تبدأ في غضون 7 أيام من ظهور أعراض كوفيد-19.</p></td><td style="vertical-align:top"><p dir="RTL">يوميًا لمدة 3 أيام تبدأ في غضون 7 أيام من ظهور أعراض كوفيد-19.</p></td><td style="vertical-align:top"><p dir="RTL">المرضى الذين <strong>لا يحتاجون إلى أكسجين إضافي</strong> وعرضة لخطر متزايد من الإصابة بأعراض كوفيد-19 الشديدة</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong>راجع قسم <em>تعليمات للعاملين في الرعاية الصحية</em> الذي يحتوي على تفاصيل عن طريقة إعطاء فيكلوري بالتسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أُعطيتَ كميةً من فيكلوري تزيد أو تنقص عن الكمية اللازمة</strong></p><p dir="RTL">بما أن فيكلوري لن يُعطى لك إلا من قِبل عامل في الرعاية الصحية، فمن المستبعد أن تُعطى كمية تزيد أو تنقص عن الكمية اللازمة. إذا أُعطيتَ جرعةً زائدة، أو فاتتكَ جرعة، <strong>فأخبر ممرضك أو طبيبك على الفور.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى عن استعمال هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرض.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو حال جميع الأدوية، يمكن أن يُسبب هذا الدواء تأثيرات جانبية، ولكنها لا تصيب كل الأشخاص.</p><p dir="RTL">قد تكون بعض التأثيرات الجانبية خطيرة أو قد تصبح خطيرة:</p><p dir="RTL"><strong>نادرة</strong></p><p dir="RTL">(قد تصيب ما يصل إلى 1 من كل 1000 مريض)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات أرجية أثناء التسريب وبعده. يمكن أن تشمل الأعراض:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في ضغط الدم أو سرعة القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الأكسجين في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، وَزيز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم في الوجه أو الشفتين أو اللسان أو الحلق (وذمة وعائية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رغبة في التقيُّؤ (غثيان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استفراغ (قيء)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرُّق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاد (قشعريرة)</p><p dir="RTL"><strong>غير معتاد</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في موضع الحقن.</p><p dir="RTL"><strong>غير معروفة</strong></p><p dir="RTL">(لا يمكن تقدير معدلها من البيانات المتاحة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تأقيه، صدمة تأقيه (تفاعلات أرجية مفاجئة مهددة للحياة)</p><p dir="RTL">لها نفس أعراض التفاعلات الأرجية، ولكن التفاعل يكون أشد ويتطلب رعاية طبية فورية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء القلب الجيبي (نبض القلب أبطأ من الطبيعي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتسرب هذا الدواء من الوريد أو يُحقن بالخطأ في النسيج المحيط بالوريد.</p><p dir="RTL"><strong>أخبر طبيبك أو ممرِّضك فوراً </strong>إذا لاحظت أياً من هذه التأثيرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية أخرى:</strong></p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة جداً</strong></p><p dir="RTL">(قد تصيب أكثر من 1 من كل 10 مرضى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُظهر الاختبارات الدموية ارتفاعاً في إنزيمات الكبد، وهي تُسمَّى <em>ناقلات الأَمين</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُظهر الاختبارات الدموية أن الدم يستغرق وقتاً أطول للتجلط</p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة</strong></p><p dir="RTL">(قد تصيب حتى 1 من كل 10 مرضى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رغبة في التقيُّؤ (غثيان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا أصبت بأي تأثيرات جانبية، فتحدث مع طبيبك أو ممرِّضك. وهذا يشمل أي تأثيرات جانبية محتملة لم تُذكر في هذه النشرة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">من خلال إبلاغك عن التأثيرات الجانبية، يمكنك المساعدة في توفير مزيدٍ من المعلومات عن مأمونية هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى الأطفال ومتناولهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الملصق والعلبة الكرتونية بعد الأحرف EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قبل استعماله،</strong> يجب تخزين هذا الدواء في درجة حرارة أقل من 30 درجة مئوية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالما يتم إعداده،</strong> يجب تخفيف فيكلوري على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالما يتم تخفيفه،</strong> يجب إعطاء فيكلوري للمريض على الفور. في حال الضرورة، يمكن تخزين أكياس المحلول المُخفَّف لمدة تصل إلى 24 ساعة في درجة حرارة الغرفة (20 إلى 25 درجة مئوية)، أو لمدة تصل إلى &nbsp;48ساعة في الثلاجة (2 إلى 8 درجات مئوية) .لا تسمَح بمرور أكثر من 48 ساعة بين وقت التخفيف ووقتِ الإعطاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. فسوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة الفعالة</strong> هي ريمديسيفير. يحتوي كل فيال على 100 ملجم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى</strong> هي: بيتادِكس سلفوبوتيل إيثر الصوديوم، وحمض الهيدروكلوريك، وهيدروكسيد الصوديوم.&lrm;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فيكلوري 100 ملجم مسحوق رُكازة لتحضير محلول للتسريب هو مسحوق أبيض اللون، أو أبيض مائل إلى الصُّفرة، أو أصفر، يتم استنشاؤه (إعدادُه) ثم تخفيفه في محلول كلوريد الصوديوم قبل إعطائه عن طريق التسريب الوريدي. وهو مُعبَّأ في فيال وحيد الاستعمال مصنوع من الزجاج الصافي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر فيكلوري في علب كرتونية تحتوي على فيال واحد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Gilead Sciences Ireland UC</p><p dir="RTL">Carrigtohill</p><p dir="RTL">County Cork, T45&nbsp;DP77</p><p dir="RTL">Ireland</p><p dir="RTL"><strong>مواقع تصنيع المواد السَّائبة:</strong></p><p dir="RTL">Jubilant&nbsp;HollisterStier, LLC<br />3525 N. Regal Street<br />Spokane, WA 99207<br />USA</p><p dir="RTL">أو</p><p dir="RTL">Patheon&nbsp;Manufacturing Services LLC<br />5900 Martin Luther King Jr Highway<br />Greenville, NC 27834<br />USA</p><p dir="RTL">أو</p><p dir="RTL">Hikma&nbsp;Farmaceutica&nbsp;(Portugal) S.A.<br />Estrada Rio Da Mo, 8/8A/8B<br />Terrugem&nbsp;SNT, 2705-906<br />Portugal</p><p dir="RTL">أو</p><p dir="RTL">Patheon&nbsp;Italia S.p.A.<br />Viale&nbsp;Gian&nbsp;Battista&nbsp;Stucchi&nbsp;110<br />Monza, 20900<br />Italy</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Veklury 100 mg powder for concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 100 mg of remdesivir. After reconstitution, each vial contains 5 mg/mL of remdesivir solution.

Excipients with known effect

Each vial contains 3 g betadex sulfobutyl ether sodium

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion (powder for concentrate).
White to off-white to yellow powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Veklury is indicated for the treatment of coronavirus disease 2019 (COVID‑19) in:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults and paediatric patients&nbsp; at least 4 weeks of age and weighing at least 3&nbsp;kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults and paediatric patients (weighing at least 40&nbsp;kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19</p><p>(see section&nbsp;5.1)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be monitored when receiving remdesivir (see section&nbsp;4.4).</p><p>Patients receiving remdesivir in an outpatient setting should be monitored according to local medical practice. Use under conditions where treatment of severe hypersensitivity reactions, including anaphylaxis, is possible.</p><p><u>Posology</u></p><p><strong>Table 1: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended dose in adults and paediatric patients </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:586px"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Given by intravenous infusion </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adults</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric patients (weighing at least 40&nbsp;kg)</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric patients at least 4&nbsp;weeks old (weighing at least 3&nbsp;kg but less than 40&nbsp;kg)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Day 1</strong></p><p><strong>(single loading dose)</strong></p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td><td style="vertical-align:top"><p>5 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p><strong>Day 2 and onwards</strong></p><p><strong>(once daily)</strong></p></td><td style="vertical-align:top"><p>100&nbsp;mg</p></td><td style="vertical-align:top"><p>100&nbsp;mg</p></td><td style="vertical-align:top"><p>2.5 mg/kg</p></td></tr></tbody></table><p><strong>Table 2: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment duration</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:586px"><thead><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><strong>Adults </strong></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><strong>Paediatric patients (weighing at least 40&nbsp;kg)</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric patients at least 4&nbsp;weeks old (weighing at least 3&nbsp;kg but less than 40&nbsp;kg)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Patients with<strong> pneumonia and requiring supplemental oxygen</strong></p></td><td style="vertical-align:top"><p>Daily for<strong> at least 5&nbsp;days and not more than 10&nbsp;days.</strong></p></td><td style="vertical-align:top"><p>Daily<strong> </strong>for<strong> at least 5&nbsp;days </strong>and <strong>not more than 10&nbsp;days</strong>.</p></td><td style="vertical-align:top"><p>Daily for up to a<strong> total of</strong> <strong>10&nbsp;days</strong>.</p></td></tr><tr><td style="vertical-align:top"><p>Patients who<strong> do not require supplemental oxygen and are at increased risk for progressing to severe COVID-19</strong></p></td><td style="vertical-align:top"><p>Daily for <strong>3&nbsp;days</strong>, starting as soon as possible after diagnosis of COVID-19 and within 7&nbsp;days of the onset of symptoms.</p></td><td style="vertical-align:top"><p>Daily for <strong>3&nbsp;days</strong>, starting as soon as possible after diagnosis of COVID-19 and within 7&nbsp;days of the onset of symptoms.</p></td><td style="vertical-align:top"><p>Not applicable.</p></td></tr></tbody></table><p><u>Special populations</u></p><p><em>Elderly</em></p><p>No dose adjustment of remdesivir is required in patients over the age of 65&nbsp;years (see sections&nbsp;5.1 and 5.2).</p><p><em>Renal impairment</em></p><p>The pharmacokinetics of remdesivir have not been evaluated in patients with renal impairment. Patients with eGFR &ge; 30&nbsp;mL/min have received remdesivir for treatment of COVID-19 with no dose adjustment. Remdesivir should not be used in patients with eGFR &lt; 30&nbsp;mL/min (see sections&nbsp;4.4 and 5.2).</p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of remdesivir have not been evaluated in patients with hepatic impairment. It is not known if dosage adjustment is appropriate in patients with hepatic impairment (see sections&nbsp;4.4 and 5.2).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of remdesivir in children less than 4&nbsp;weeks of age and weighing less than 3&nbsp;kg have not yet been established. No data are available.</p><p><em>Immunocompromised population</em></p><p>The safety and efficacy of remdesivir in immunocompromised patients have not yet been established. Only limited data are available (see section 4.4).</p><p><u>Method of administration</u></p><p>For intravenous use.</p><p>Remdesivir is for administration by intravenous infusion after reconstitution and further dilution.</p><p>It must not be given as an intramuscular (IM) injection.</p><p>For instructions on reconstitution and dilution of the medicinal product before administration, see section&nbsp;6.6.</p><p><strong>Table&nbsp;3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended rate of infusion&nbsp;&ndash; for reconstituted and diluted remdesivir powder for concentrate for solution for infusion in adults and paediatric patients weighing at least 40&nbsp;kg</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p>Infusion Bag Volume</p></td><td><p>Infusion Time</p></td><td><p>Rate of Infusion</p></td></tr></thead><tbody><tr><td rowspan="3"><p>250&nbsp;mL</p></td><td><p>30&nbsp;min</p></td><td><p>8.33&nbsp;mL/min</p></td></tr><tr><td><p>60&nbsp;min</p></td><td><p>4.17&nbsp;mL/min</p></td></tr><tr><td><p>120&nbsp;min</p></td><td><p>2.08&nbsp;mL/min</p></td></tr><tr><td rowspan="3"><p>100&nbsp;mL</p></td><td><p>30&nbsp;min</p></td><td><p>3.33&nbsp;mL/min</p></td></tr><tr><td><p>60&nbsp;min</p></td><td><p>1.67&nbsp;mL/min</p></td></tr><tr><td><p>120&nbsp;min</p></td><td><p>0.83&nbsp;mL/min</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended rate of infusion&nbsp;&ndash; for reconstituted and diluted remdesivir powder for concentrate for solution for infusion in paediatric patients at least 4&nbsp;weeks of age and weighing at least 3&nbsp;kg but less than 40&nbsp;kg</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p>Infusion Bag Volume</p></td><td><p>Infusion Time</p></td><td><p>Rate of Infusion<sup>a</sup></p></td></tr></thead><tbody><tr><td rowspan="3"><p>100&nbsp;mL</p></td><td><p>30&nbsp;min</p></td><td><p>3.33&nbsp;mL/min</p></td></tr><tr><td><p>60&nbsp;min</p></td><td><p>1.67&nbsp;mL/min</p></td></tr><tr><td><p>120&nbsp;min</p></td><td><p>0.83&nbsp;mL/min</p></td></tr><tr><td rowspan="3"><p>50&nbsp;mL</p></td><td><p>30&nbsp;min</p></td><td><p>1.67&nbsp;mL/min</p></td></tr><tr><td><p>60&nbsp;min</p></td><td><p>0.83&nbsp;mL/min</p></td></tr><tr><td><p>120&nbsp;min</p></td><td><p>0.42&nbsp;mL/min</p></td></tr><tr><td rowspan="3"><p>25&nbsp;mL</p></td><td><p>30&nbsp;min</p></td><td><p>0.83&nbsp;mL/min</p></td></tr><tr><td><p>60&nbsp;min</p></td><td><p>0.42&nbsp;mL/min</p></td></tr><tr><td><p>120&nbsp;min</p></td><td><p>0.21&nbsp;mL/min</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rate of infusion may be adjusted based on total volume to be infused.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity including infusion-related and anaphylactic reactions</u></p><p>Hypersensitivity reactions including infusion-related and anaphylactic reactions have been observed during and following administration of remdesivir. Signs and symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnoea, wheezing, angioedema, rash, nausea, vomiting, diaphoresis, and shivering. Slower infusion rates, with a maximum infusion time of up to 120&nbsp;minutes, can be considered to potentially prevent these signs and symptoms. Monitor patients for hypersensitivity reactions during and following administration of remdesivir as clinically appropriate. Patients receiving remdesivir in an outpatient setting should be monitored after administration according to local medical practice. If signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue administration of remdesivir and initiate appropriate treatment.</p><p><u>Transaminase elevations</u></p><p>Transaminase elevations have been observed in the remdesivir clinical trials, including in healthy volunteers and patients with COVID‑19. Liver function should be determined in all patients prior to starting remdesivir and should be monitored while receiving it as clinically appropriate. No clinical studies with remdesivir have been conducted in patients with hepatic impairment. Remdesivir should only be used in patients with hepatic impairment if the potential benefit outweighs the potential risk.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remdesivir should not be initiated in patients with alanine aminotransferase (ALT) &ge;5&nbsp;times the upper limit of normal at baseline</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remdesivir should be discontinued in patients who develop:</p><p>◦&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ALT &ge;5&nbsp;times the upper limit of normal during treatment with remdesivir. It may be restarted when ALT is &lt; 5&nbsp;times the upper limit of normal.</p><p><u>OR</u></p><p>◦&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ALT elevation accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or international normalised ratio (INR) (see sections&nbsp;4.8 and 5.2).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>In animal studies on rats and monkeys, severe renal toxicity was observed (see section&nbsp;5.3). The mechanism of this renal toxicity is not fully understood. A relevance for humans cannot be excluded.</p><p>All patients should have eGFR determined prior to starting remdesivir and while receiving it as clinically appropriate. Remdesivir should not be used in patients with eGFR &lt; 30&nbsp;mL/min.</p><p>&nbsp;</p><p><u>Risk of reduced antiviral activity when coadministered with chloroquine or hydroxychloroquine</u></p><p>Coadministration of remdesivir and chloroquine phosphate or hydroxychloroquine sulphate is not recommended based on <em>in vitro</em> data demonstrating an antagonistic effect of chloroquine on the intracellular metabolic activation and antiviral activity of remdesivir (see sections&nbsp;4.5 and 5.1)</p><p>&nbsp;</p><p><u>Immunocompromised patients:</u></p><p>It is unclear if the treatment duration of three days is sufficient to clear the virus in immunocompromised patients, in whom prolonged viral shedding occurs. There is a potential risk of resistance development. Only limited data are available.</p><p>Excipients</p><p>Veklury contains betadex sulfobutyl ether sodium, which is renally cleared and accumulates in patients with decreased renal function, which may potentially adversely affect renal function. Therefore Veklury should not be used in patients with eGFR &lt;&nbsp;30&nbsp;mL/min (see sections&nbsp;4.2 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No clinical interaction studies have been performed with remdesivir. The overall potential for interactions is currently unknown; patients should remain under close observation during the days of remdesivir administration. Due to antagonism observed <em>in vitro</em>, concomitant use of remdesivir with chloroquine phosphate or hydroxychloroquine sulphate is not recommended.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on remdesivir</u></p><p><em>In&nbsp;vitro</em>, remdesivir is a substrate for esterases in plasma and tissue, drug metabolizing enzymes CYP2C8, CYP2D6, and CYP3A4, and is a substrate for Organic Anion Transporting Polypeptides&nbsp;1B1 (OATP1B1) and P‑glycoprotein (P‑gp) transporters.</p><p>The potential of interaction of remdesivir with inhibitors/inducers of the hydrolytic pathway (esterase) or CYP2C8, 2D6 or 3A4 has not been studied. The risk of clinically relevant interaction is unknown. Strong inhibitors may result in increased remdesivir exposure. The use of strong inducers (e.g. rifampicin) may decrease plasma concentrations of remdesivir and is not recommended.</p><p>Dexamethasone is reported to be a moderate inducer of CYP3A and P-gp. Induction is dose-dependent and occurs after multiple doses. Dexamethasone is unlikely to have a clinically significant effect on remdesivir as remdesivir has a moderate-high hepatic extraction ratio and is used for a short duration in the treatment of COVID-19.</p><p>&nbsp;</p><p><u>Effects of remdesivir on other medicinal products</u></p><p><em>In&nbsp;vitro</em>, remdesivir is an inhibitor of CYP3A4, OATP1B1 and OATP1B3. The clinical relevance of these <em>in&nbsp;vitro</em> drug interactions has not been established. Remdesivir may transiently increase plasma concentrations of medicinal products that are substrates of CYP3A or OATP 1B1/1B3. No data is available, however it can be suggested that medicinal products that are substrates of CYP3A4 or substrates of OATP&nbsp;1B1/1B3 should be administered at least 2&nbsp;hours after remdesivir. Remdesivir induced CYP1A2 and potentially CYP3A <em>in&nbsp;vitro.</em> Co-administration of remdesivir with CYP1A2 or CYP3A4 substrates with narrow therapeutic index may lead to loss of their efficacy.</p><p>Dexamethasone is a substrate of CYP3A4 and although remdesivir inhibits CYP3A4, due to remdesivir&#39;s rapid clearance after IV administration, remdesivir is unlikely to have a significant effect on dexamethasone exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of remdesivir in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at exposures of the major metabolite of remdesivir that were around human therapeutic exposures (see section&nbsp;5.3). Remdesivir should not be used during pregnancy unless the clinical condition of the women requires treatment with it.</p><p>Women of child-bearing potential have to use effective contraception during treatment.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether remdesivir is excreted in human milk or the effects on the breast-fed infant, or the effects on milk production.</p><p>In animal studies, the nucleoside analog metabolite GS‑441524 has been detected in the blood of nursing rat pups of mothers given remdesivir. Therefore, excretion of remdesivir and/or metabolites into the milk of lactating animals can be assumed.</p><p>Because of the potential for viral transmission to SARS-CoV‑2‑negative infants and adverse reactions from the drug in breast-feeding infants, a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from remdesivir therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No human data on the effect of remdesivir on fertility are available. In male rats, there was no effect on mating or fertility with remdesivir treatment. In female rats, however, an impairment of fertility was observed (see section&nbsp;5.3). The relevance for humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Remdesivir is predicted to have no or negligible influence on these abilities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most common adverse reaction in healthy volunteers is increased transaminases (14%). The most common adverse reaction in patients with COVID-19 is nausea (4%).</p><p>Tabulated summary of adverse reactions</p><p>The adverse reactions in Table&nbsp;5are listed below by system organ class and frequency. Frequencies are defined as follows: Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); not known (cannot be estimated from the available data).</p><p><strong>Table&nbsp;5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated list of adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p>Frequency</p></td><td><p>Adverse reaction</p></td></tr></thead><tbody><tr><td colspan="2"><p>Immune system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>anaphylactic reaction, anaphylactic shock</p></td></tr><tr><td colspan="2"><p>Nervous system disorders</p></td></tr><tr><td><p>Common</p></td><td><p>headache</p></td></tr><tr><td colspan="2"><p>Cardiac disorders</p></td></tr><tr><td><p>Not known</p></td><td><p>sinus bradycardia*</p></td></tr><tr><td colspan="2"><p>Gastrointestinal disorders</p></td></tr><tr><td><p>Common</p></td><td><p>nausea</p></td></tr><tr><td colspan="2"><p>Hepatobiliary disorders</p></td></tr><tr><td><p>Very common</p></td><td><p>transaminases increased</p></td></tr><tr><td colspan="2"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td><p>Common</p></td><td><p>rash</p></td></tr><tr><td colspan="2"><p><em>Investigations</em></p></td></tr><tr><td><p>Very common</p></td><td><p>prothrombin time prolonged</p></td></tr><tr><td colspan="2"><p>Injury, poisoning and procedural complications</p></td></tr><tr><td><p>Rare</p></td><td><p>infusion-related reaction</p></td></tr><tr><td colspan="2"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td><p>Uncommon</p></td><td><p>injection site erythema</p></td></tr><tr><td><p>Not known</p></td><td><p>administration site extravasation</p></td></tr></tbody></table><p>*Reported in post-marketing, usually normalised within 4 days following last remdesivir administration without additional intervention</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Transaminases Increased</p><p>In healthy volunteer studies, increases in ALT, aspartate aminotransferase (AST) or both in subjects who received remdesivir were grade&nbsp;1 (10%) or grade&nbsp;2 (4%). In a randomised, double-blind, placebo-controlled clinical study of patients with COVID-19 (NIAID ACTT‑1), any grade (&ge;&nbsp;1.25&nbsp;&times; upper limit of normal (ULN)) laboratory abnormalities of increased AST and increased ALT occurred in 33% and 32% of patients, respectively, receiving remdesivir compared with 44% and 43% of patients, respectively, receiving placebo. Grade&nbsp;&ge; 3 (&ge;&nbsp;5.0&nbsp;&times; ULN) laboratory abnormalities of increased AST and increased ALT occurred in 6% and 3% of patients, respectively, receiving remdesivir compared with 8% and 6% of patients, respectively, receiving placebo. In a randomised, open-label multi-centre clinical trial (Study GS-US-540‑5773) in hospitalised patients with severe COVID‑19 receiving remdesivir for 5 (n=200) or 10&nbsp;days (n=197), any grade laboratory abnormalities of increased AST and increased ALT occurred in 40% and 42% of patients, respectively, receiving remdesivir. Grade&nbsp;&ge; 3 laboratory abnormalities of increased AST and increased ALT both occurred in 7% of patients receiving remdesivir. In a randomised, open-label multi-centre clinical trial (Study GS-US-540‑5774) in hospitalised patients with moderate COVID‑19 receiving remdesivir for 5 (n=191) or 10&nbsp;days (n=193) compared to standard of care (n=200), any grade laboratory abnormalities of increased AST and increased ALT occurred in 32% and 33% of patients, respectively, receiving remdesivir, and 33% and 39% of patients, respectively, receiving standard of care. Grade&nbsp;&ge; 3 laboratory abnormalities of increased AST and increased ALT occurred in 2% and 3% of patients, respectively, receiving remdesivir and 6% and 8%, respectively, receiving standard of care.</p><p><em>Prothrombin time prolonged </em></p><p>In a clinical study (NIAID ACTT-1) of patients with COVID-19, the incidence of prolonged prothrombin time or INR (predominantly Grades 1-2) was higher in subjects who received remdesivir compared to placebo, with no difference observed in the incidence of bleeding events between the two groups. Prothrombin time should be monitored while receiving remdesivir as clinically appropriate.</p><p>In Study GS-US-540-9012, the incidence of increased prothrombin time or INR was similar in patients treated with remdesivir compared to placebo.</p><p><em>Paediatric population</em></p><p>The safety assessment of remdesivir in children 4&nbsp;weeks of age and older and weighing at least 3&nbsp;kg with COVID-19 is based on data from a Phase&nbsp;2/3, open-label clinical trial (Study GS‑US‑540‑5823) that enrolled 53&nbsp;patients who were treated with remdesivir (see Section 5.1). The adverse reactions observed were consistent with those observed in clinical trials of remdesivir in adults.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:-19.6pt;margin-top:3.4pt;width:477.45pt;height:60.55pt;z-index:251657728;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox style='mso-fit-shape-to-text:t'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of overdose with remdesivir should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with remdesivir.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, direct acting antivirals, ATC code: J05AB16.</p><p><u>Mechanism of action</u></p><p>Remdesivir is an adenosine nucleotide prodrug that is metabolized within host cells to form the pharmacologically active nucleoside triphosphate metabolite. Remdesivir triphosphate acts as an analog of adenosine triphosphate (ATP) and competes with the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV‑2 RNA-dependent RNA polymerase, which results in delayed chain termination during replication of the viral RNA. As an additional mechanism, remdesivir triphosphate can also inhibit viral RNA synthesis following its incorporation into the template viral RNA as a result of read-through by the viral polymerase that may occur in the presence of higher nucleotide concentrations. When remdesivir nucleotide is present in the viral RNA template, the efficiency of incorporation of the complementary natural nucleotide is compromised, thereby inhibiting viral RNA synthesis.</p><p><u>Antiviral activity</u></p><p>Remdesivir exhibited <em>in&nbsp;vitro</em> activity against a clinical isolate of SARS-CoV‑2 in primary human airway epithelial cells with a 50% effective concentration (EC<sub>50</sub>) of 9.9&nbsp;nM after 48&nbsp;hours of treatment. Remdesivir inhibited the replication of SARS-CoV-2 in the continuous human lung epithelial cell lines Calu-3 and A549-hACE2 with EC<sub>50</sub> values of 280 nM after 72 hours of treatment and 115 nM after 48 hours of treatment, respectively. The EC<sub>50</sub> values of remdesivir against SARS-CoV‑2 in Vero cells were 137&nbsp;nM at 24&nbsp;hours and 750&nbsp;nM at 48&nbsp;hours post-treatment. The antiviral activity of remdesivir was antagonised by chloroquine phosphate in a dose-dependent manner when the two drugs were co-incubated at clinically relevant concentrations in HEp-2 cells infected with respiratory syncytial virus (RSV). Higher remdesivir EC<sub>50</sub> values were observed with increasing concentrations of chloroquine phosphate. Increasing concentrations of chloroquine phosphate reduced formation of remdesivir triphosphate in A549-hACE2, HEp-2 and normal human bronchial epithelial cells.</p><p>Based on <em>in vitro</em> testing, remdesivir retained similar antiviral activity (&lt;2.5-fold change) against clinical isolates of SARS-CoV-2 variants containing the P323L substitution in the viral polymerase including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Epsilon (B.1.429), Kappa (B.1.617.1), Lambda (C.37), Iota (B.1.526) and Zeta (P.2) variants compared to earlier lineage SARS-CoV-2 (lineage A) isolates. For the clinical isolates of the Delta (B.1.617.2) and Omicron (B.1.1.529 sub-lineages BA.1 and BA.2) variants, remdesivir also maintained antiviral activity (&lt;&nbsp;0.6-fold change) relative to the lineage A SARS-CoV-2 isolates. The antiviral activity of remdesivir against SARS-CoV-2 variants is presented in Table 6.Table&nbsp;6: Remdesivir antiviral activity against clinical isolates of SARS-CoV-2 variants&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:top"><p><strong>SARS-CoV-2 Lineage</strong></p></td><td style="vertical-align:top"><p><strong>Country First Identified</strong></p></td><td style="vertical-align:top"><p><strong>WHO Nomenclature</strong></p></td><td style="vertical-align:top"><p><strong>Key </strong></p><p><strong>Substitutions</strong></p></td><td style="vertical-align:top"><p><strong>Remdesivir</strong></p><p><strong>EC<sub>50</sub> (nM)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Fold Change in Susceptibility</strong></p></td><td style="vertical-align:top"><p><strong>Change in Susceptibility</strong></p></td></tr><tr><td style="vertical-align:top"><p>A</p></td><td style="vertical-align:top"><p>USA</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>110</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>B.1.1.7</p></td><td style="vertical-align:top"><p>UK</p></td><td style="vertical-align:top"><p>Alpha</p></td><td style="vertical-align:top"><p>P323L</p></td><td style="vertical-align:top"><p>192</p></td><td style="vertical-align:top"><p>1.58</p></td><td style="vertical-align:top"><p>No change<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>B.1.351</p></td><td style="vertical-align:top"><p>South Africa</p></td><td style="vertical-align:top"><p>Beta</p></td><td style="vertical-align:top"><p>P323L</p></td><td style="vertical-align:top"><p>141</p></td><td style="vertical-align:top"><p>1.19</p></td><td style="vertical-align:top"><p>No change<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>P.1</p></td><td style="vertical-align:top"><p>Brazil</p></td><td style="vertical-align:top"><p>Gamma</p></td><td style="vertical-align:top"><p>P323L</p></td><td style="vertical-align:top"><p>97</p></td><td style="vertical-align:top"><p>0.82</p></td><td style="vertical-align:top"><p>No change<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>B.1.617.2</p></td><td style="vertical-align:top"><p>India</p></td><td style="vertical-align:top"><p>Delta</p></td><td style="vertical-align:top"><p>P323L, G671S</p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>0.59</p></td><td style="vertical-align:top"><p>No change<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>B.1.429</p></td><td style="vertical-align:top"><p>USA</p></td><td style="vertical-align:top"><p>Epsilon</p></td><td style="vertical-align:top"><p>P323L</p></td><td style="vertical-align:top"><p>210</p></td><td style="vertical-align:top"><p>1.94</p></td><td style="vertical-align:top"><p>No change<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>P.2</p></td><td style="vertical-align:top"><p>Brazil</p></td><td style="vertical-align:top"><p>Zeta</p></td><td style="vertical-align:top"><p>P323L</p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>1.17</p></td><td style="vertical-align:top"><p>No change<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>B.1.526</p></td><td style="vertical-align:top"><p>USA</p></td><td style="vertical-align:top"><p>Iota</p></td><td style="vertical-align:top"><p>P323L</p></td><td style="vertical-align:top"><p>258</p></td><td style="vertical-align:top"><p>2.33</p></td><td style="vertical-align:top"><p>No change<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>B.1.617.1</p></td><td style="vertical-align:top"><p>India</p></td><td style="vertical-align:top"><p>Kappa</p></td><td style="vertical-align:top"><p>P323L</p></td><td style="vertical-align:top"><p>77</p></td><td style="vertical-align:top"><p>0.63</p></td><td style="vertical-align:top"><p>No change<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>C.37</p></td><td style="vertical-align:top"><p>Peru</p></td><td style="vertical-align:top"><p>Lambda</p></td><td style="vertical-align:top"><p>P323L</p></td><td style="vertical-align:top"><p>175</p></td><td style="vertical-align:top"><p>1.37</p></td><td style="vertical-align:top"><p>No change<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>B.1.1.529</p><p>BA.1</p><p>BA.2</p></td><td style="vertical-align:top"><p>South Africa</p></td><td style="vertical-align:top"><p>Omicron</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>P323L</p><p>P323L</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>44</p><p>25</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.45</p><p>0.23</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No change<sup>a</sup></p><p>No change<sup>a</sup></p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp; Fold-change: &lt;2.5- is not significant. All variants show no reduction in susceptibility.</p><p>&nbsp;</p><p><u>Resistance</u></p><p><em>In Cell Culture</em></p><p>SARS-CoV-2 isolates with reduced susceptibility to remdesivir have been selected in cell culture. In one selection with GS-441524, the parent nucleoside of remdesivir, virus pools emerged expressing combinations of amino acid substitutions at V166A, N198S, S759A, V792I, C799F, and C799R in the viral RNA-dependent RNA polymerase, conferring EC<sub>50</sub> fold-changes of 2.7 up to 10.4. When individually introduced into a wild-type recombinant virus by site-directed mutagenesis, 1.7- to 3.5-fold reduced susceptibility to remdesivir was observed. In a second selection with remdesivir using a SARS-CoV-2 isolate containing the P323L substitution in the viral polymerase, a single amino acid substitution at V166L emerged. Recombinant viruses with substitutions at P323L alone or P323L+V166L in combination exhibited 1.3- and 1.5-fold changes in remdesivir susceptibility, respectively.</p><p>Cell culture resistance profiling of remdesivir using the rodent CoV murine hepatitis virus identified two&nbsp;substitutions (F476L and V553L) in the viral RNA-dependent RNA polymerase at residues conserved across CoVs that conferred 5.6‑fold reduced susceptibility to remdesivir. Introduction of the corresponding substitutions (F480L and V557L) into SARS-CoV resulted in 6‑fold reduced susceptibility to remdesivir in cell culture and attenuated SARS-CoV pathogenesis in a mouse model. When individually introduced into a SARS-CoV-2 recombinant virus, the corresponding substitutions at F480L and V557L each conferred 2-fold reduced susceptibility to remdesivir.</p><p><em>In </em><em>Clinical</em><em> Trials</em></p><p>In NIAID ACTT-1 Study (CO-US-540-5776), among 61 patients with baseline and post-baseline sequencing data available, the rate of emerging substitutions in the viral RNA-dependent RNA polymerase was similar in patients treated with VEKLURY compared to placebo. In 2 patients treated with VEKLURY, substitutions in the RNA-dependent RNA polymerase previously identified in resistance selection experiments (V792I or C799F) and associated with low fold change in remdesivir susceptibility (&le;3.4-fold) were observed. No other RNA-dependent RNA polymerase substitutions observed in patients treated with VEKLURY were associated with resistance to remdesivir.</p><p>In Study GS-US-540-5823, among patients with baseline and post-baseline sequencing data available, substitutions in the viral RNA-dependent RNA polymerase (A656P and G670V) were observed in one of 23&nbsp;patients treated with remdesivir. The substitutions observed have not been associated with resistance to remdesivir.</p><p><u>Clinical efficacy and safety</u></p><p><em>Clinical trials in patients with COVID‑19</em></p><p><u>NIAID ACTT‑1 Study (CO-US-540-5776)</u></p><p>A randomised, double-blind, placebo-controlled clinical trial evaluated remdesivir 200&nbsp;mg once daily for 1&nbsp;day followed by remdesivir 100&nbsp;mg once daily for up to 9&nbsp;days (for a total of up to 10&nbsp;days of intravenously administered therapy) in hospitalised adult patients with COVID‑19 with evidence of lower respiratory tract involvement. The trial enrolled 1,062 hospitalised patients: 159 (15%) patients with mild/moderate disease (15% in both treatment groups) and 903 (85%) patients with severe disease (85% in both treatment groups). Mild/moderate disease was defined as SpO2 &gt;&nbsp;94% and respiratory rate &lt;&nbsp;24 breaths/minute without supplemental oxygen; severe disease was defined as SpO2 &le; 94% on room air, a respiratory rate &ge; 24&nbsp;breaths/min, and an oxygen requirement, or a requirement for mechanical ventilation. A total of 285 patients (26.8%) (n=131 received remdesivir) were on mechanical ventilation/Extracorporeal Membrane Oxygenation (ECMO). Patients were randomised 1:1, stratified by disease severity at enrolment, to receive remdesivir (n=541) or placebo (n=521), plus standard of care.</p><p>The baseline mean age was 59&nbsp;years and 36% of patients were aged 65 or older. Sixty-four percent were male, 53% were White, 21% were Black, 13% were Asian. The most common comorbidities were hypertension (51%), obesity (45%), type&nbsp;2 diabetes mellitus (31%); the distribution of comorbidities was similar between the two treatment groups.</p><p>Approximately 38.4% (208/541) of the patients received a 10‑day treatment course with remdesivir.</p><p>The primary clinical endpoint was time to recovery within 29&nbsp;days after randomisation, defined as either discharged from hospital (with or without limitations of activity and with or without home oxygen requirements) or hospitalised but not requiring supplemental oxygen and no longer requiring ongoing medical care. The median time to recovery was 10&nbsp;days in the remdesivir group compared to 15&nbsp;days in the placebo group (recovery rate ratio 1.29; [95%&nbsp;CI 1.12 to 1.49], p &lt; 0.001).</p><p>No difference in time to recovery was seen in the stratum of patients with mild-moderate disease at enrolment (n=159). The median time to recovery was 5 days in the remdesivir and 7 days in the placebo groups (recovery rate ratio 1.10; [95%&nbsp;CI 0.8 to 1.53]); the odds of improvement in the ordinal scale in the remdesivir group at Day 15 when compared to the placebo group were as follows: odds ratio, 1.2; [95%&nbsp;CI 0.7 to 2.2, p&nbsp;=&nbsp;0.562].</p><p>Among patients with severe disease at enrolment (n=903), the median time to recovery was 12 days in the remdesivir group compared to 19 days in the placebo group (recovery rate ratio, 1.34; [95%&nbsp;CI 1.14 to 1.58]; p&nbsp;&lt;&nbsp;0.001); the odds of improvement in the ordinal scale in the remdesivir group at Day 15 when compared to the placebo group were as follows: odds ratio, 1.6; [95%&nbsp;CI 1.3 to 2.0].</p><p>Overall, the odds of improvement in the ordinal scale were higher in the remdesivir group at Day 15 when compared to the placebo group (odds ratio, 1.6; [95%&nbsp;CI 1.3 to 1.9], p&nbsp;&lt;&nbsp;0.001).</p><p>The 29-day mortality in the overall population was 11.6% for the remdesivir group vs 15.4% for the placebo group (hazard ratio, 0.73; [95% CI 0.52 to 1.03]; p=0.07). A post-hoc analysis of 29-day mortality by ordinal scale is reported in Table 7.</p><p>&nbsp;</p><p><strong>Table7:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29-Day Mortality Outcomes by Ordinal Scale<sup>a</sup> at Baseline&mdash;NIAID ACTT-1 Trial</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Ordinal Score at Baseline</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>5</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>6</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Requiring low-flow oxygen</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Requiring high-flow oxygen or non-invasive mechanical ventilation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Remdesivir</p><p>(N=232)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N=203)</p></td><td style="vertical-align:top"><p>Remdesivir</p><p>(N=95)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N=98)</p></td></tr><tr><td style="vertical-align:top"><p><strong>29-day mortality </strong></p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>12.8</p></td><td style="vertical-align:top"><p>21.8</p></td><td style="vertical-align:top"><p>20.6</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hazard ratio<sup>b</sup> (95% CI) </strong></p></td><td colspan="2" style="vertical-align:top"><p>0.30 (0.14, 0.64)</p></td><td colspan="2" style="vertical-align:top"><p>1.02 (0.54, 1.91)</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp; Not a pre-specified analysis.</p><p>b&nbsp;&nbsp;&nbsp; Hazard ratios for baseline ordinal score subgroups are from unstratified Cox proportional hazards models.</p><p>&nbsp;</p><p><u>Study GS-US-540-5773 in Patients with Severe COVID-19 </u></p><p>A randomised, open-label multi-centre clinical trial (Study 5773) of patients at least 12 years of age with confirmed SARS-CoV-2 infection, oxygen saturation of &le;&nbsp;94% on room air, and radiological evidence of pneumonia compared 200 patients who received remdesivir for 5 days with 197 patients who received remdesivir for 10 days. All patients received 200 mg of remdesivir on Day 1 and 100 mg once daily on subsequent days, plus standard of care. The primary endpoint was clinical status on Day 14 assessed on a 7-point ordinal scale ranging from hospital discharge to increasing levels of oxygen and ventilatory support to death.</p><p>The odds of improvement at Day 14 for patients randomized to a 10-day course of remdesivir compared with those randomized to a 5-day course was 0.67 (odds ratio); [95% CI 0.46 to 0.98]. Statistically significant imbalances in baseline clinical status were observed in this study. After adjusting for between-group differences at baseline, the odds of improvement at Day 14 was 0.75 (odds ratio); [95% CI 0.51 to 1.12]. In addition, there were no statistically significant differences in recovery rates or mortality rates in the 5-day and 10-day groups once adjusted for between group differences at baseline. All-cause 28-day mortality was 12% vs 14% in the 5- and 10-day treatment groups, respectively.</p><p><u>Study GS-US-540-9012 in patients with confirmed COVID-19 at increased risk for disease progression</u></p><p>A randomised, double-blind, placebo-controlled, multi-centre clinical trial to evaluate treatment with remdesivir in an outpatient setting in 562 &nbsp;patients including 8&nbsp;adolescents (12&nbsp;years of age and older and weighing at least 40&nbsp;kg) with confirmed COVID-19 and at least one risk factor for disease progression to hospitalisation. Risk factors for disease progression were: aged &ge;60 years, chronic lung disease, hypertension, cardiovascular or cerebrovascular disease, diabetes mellitus, obesity, immunocompromised state, chronic mild or moderate kidney disease, chronic liver disease, current cancer, or sickle cell disease. Vaccinated patients were excluded from the study.</p><p>&nbsp;Patients treated with remdesivir received 200 mg on Day 1 and 100 mg once daily on subsequent days for a total of 3 days of intravenously administered therapy. Patients were randomized in a 1:1 manner, stratified by residence in a skilled nursing facility (yes/no), age (&lt; 60 vs &ge; 60 years), and region (US vs ex-US) to receive remdesivir (n=279) or placebo (n=283), plus standard of care.</p><p>At baseline, mean age was 50 years (with 30% of patients aged 60 or older); 52% were male, 80% were White, 8% were Black, 2% were Asian, 44% were Hispanic or Latino; median body mass index was 30.7 kg/m<sup>2</sup>. The most common comorbidities were diabetes mellitus (62%), obesity (56%), and hypertension (48%). Median (Q1, Q3) duration of symptoms prior to treatment was 5 (3,6) days; median viral load was 6.3 log<sub>10</sub> copies/mL at baseline. The baseline demographics and disease characteristics were balanced across the remdesivir and placebo treatment groups. Post-hoc exploratory analysis of optional biomarker samples showed 14.8% of patients were serological positive at baseline and 37.7% were serological negative (47.5% did not consent to optional biomarker collection).</p><p>The primary endpoint was the proportion of patients with COVID-19 related hospitalisation (defined as at least 24 hours of acute care) or all-cause 28-day mortality. Events (COVID-19-related hospitalisation or all-cause 28-day mortality) occurred in 2 (0.7%) patients treated with remdesivir compared to 15 (5.3%) patients concurrently randomized to placebo, demonstrating an 87% reduction in COVID-19-related hospitalisation or all-cause mortality compared to placebo (hazard ratio, 0.134 [95% CI, 0.031 to 0.586]; p=0.0076). The absolute risk reduction was 4.6% (95% CI, 1.8% to 7.5%). No deaths were observed at Day 28. Six of the 17 hospitalisation events occurred in participants with known baseline serostatus (serological positive: n=0 in remdesivir group and n=2 in placebo group; serological negative: n=2 in remdesivir group and n=2 in placebo group). Eleven of the 17 hospitalisation events occurred in participants with unknown baseline serostatus in placebo group and none in the remdesivir group. No conclusion can be made on efficacy in the subgroups stratified by serostatus due to the small number of patients with known serostatus and overall low event rates.</p><p><u>QT</u></p><p>Current non-clinical and clinical data do not suggest a risk of QT prolongation, but QT prolongation has not been fully evaluated in humans.</p><p><u>Paediatric population</u></p><p>Study GS-US-540-5823 is a single-arm, open-label study where the pharmacokinetics and safety of remdesivir in paediatric patients at least 28 days of age and weighing at least 3 kg with COVID-19 (n=53) was assessed. Efficacy endpoints were secondary and descriptively analysed and therefore these should be interpreted with caution. The study is ongoing.</p><p>Patients weighing &ge;&nbsp;40&nbsp;kg received 200&nbsp;mg of remdesivir on Day&nbsp;1 followed by remdesivir 100&nbsp;mg once daily on subsequent days (i.e., the adult dose); patients weighing &ge;&nbsp;3&nbsp;kg to &lt;&nbsp;40&nbsp;kg received remdesivir 5&nbsp;mg/kg on Day&nbsp;1 followed by remdesivir 2.5&nbsp;mg/kg once daily on subsequent days. Median (range) exposure to remdesivir was 5 (1, 10) days.&nbsp;</p><p>At baseline, median age was 7&nbsp;years (range: 0.1, 17); 57% were female; median weight was 24.6&nbsp;kg (range: 4&nbsp;kg to 192&nbsp;kg).&nbsp; A total of 19 patients (37%) were obese (BMI-for-age &ge; 95<sup>th</sup> percentile); 7&nbsp;(58%), 2 (17%), 3 (27%), 3 (27%), and 4 (80%) patients in Cohorts 1, 2, 3, 4 and 8 respectively. A total of 12&nbsp;patients (23%) were on invasive mechanical ventilation (score of 2 in a 7-point ordinal scale), 18&nbsp;(34%) were on non-invasive ventilation or high-flow oxygen (score of 3); 10&nbsp;(19%) were on low‑flow oxygen (score of 4); and 13&nbsp;(25%) were on room air (score of 5), at baseline. The overall median (Q1, Q3) duration of symptoms and hospitalisation prior to first dose of remdesivir was 5&nbsp;(3,&nbsp;7) days and 1&nbsp;(1, 3) day, respectively.</p><p>In the overall population of the study, the median (Q1, Q3) change from baseline in clinical status (assessed on a 7-point ordinal scale ranging from death [score of 1] to hospital discharge [score of 7]) was +2.0 (1.0, 4.0) points on Day&nbsp;10. Among those with an ordinal score of &le;&nbsp;5 points at baseline, the proportion who had a &ge; 2-point improvement in clinical status on Day 10 was 75.0% (39/52); median (Q1, Q3) time to recovery was 7&nbsp;(5, 16) days.</p><p>Overall, 60% of patients were discharged by Day&nbsp;10. Most patients 92% (49/53) received at least 1 concomitant medication other than remdesivir for the treatment of COVID-19 including immune modulator and anti-inflammatory agents. Three patients died during the study.</p><p>&nbsp;</p><p>See sections 4.2 and 5.2 for information on other subsets of the paediatric population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of remdesivir have been investigated in healthy volunteers. No pharmacokinetic data is available from patients with COVID‑19.</p><p><u>Absorption</u></p><p>The pharmacokinetic properties of remdesivir and the predominant circulating metabolite GS‑441524 have been evaluated in healthy adult subjects. Following intravenous administration of remdesivir adult dosage regimen, peak plasma concentration was observed at end of infusion, regardless of dose level, and declined rapidly thereafter with a half-life of approximately 1&nbsp;hour. Peak plasma concentrations of GS‑441524 were observed at 1.5 to 2.0&nbsp;hours post start of a 30 minutes infusion.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Remdesivir is approximately 93% bound to human plasma proteins (ex-vivo data) with free fraction ranging from 6.4% to 7.4%. The binding is independent of drug concentration over the range of 1 to 10 &mu;M, with no evidence for saturation of remdesivir binding. After a single 150&nbsp;mg dose of [<sup>14</sup>C]-remdesivir in healthy subjects, the blood to plasma ratio of [<sup>14</sup>C]-radioactivity was approximately 0.68 at 15&nbsp;minutes from start of infusion, increased over time reaching ratio of 1.0 at 5&nbsp;hours, indicating differential distribution of remdesivir and its metabolites to plasma or cellular components of blood.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Remdesivir is extensively metabolized to the pharmacologically active nucleoside analog triphosphate GS‑443902 (formed intracellularly). The metabolic activation pathway involves hydrolysis by esterases, which leads to the formation of the intermediate metabolite, GS‑704277. Phosphoramidate cleavage followed by phosphorylation forms the active triphosphate, GS‑443902. Dephosphorylation of all phosphorylated metabolites can result in the formation of nucleoside metabolite GS‑441524 that itself is not efficiently re-phosphorylated. &nbsp;Decyanation of remdesivir and/or its metabolites, followed by subsequent rhodanese mediated conversion generates thiocyanate anion. The levels of thiocyanate detected following administration of 100&nbsp;mg and 200&nbsp;mg remdesivir were observed to be significantly below endogenous levels in human plasma.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Following a single 150&nbsp;mg IV dose of [<sup>14</sup>C]-remdesivir, mean total recovery of the dose was 92%, consisting of approximately 74% and 18% recovered in urine and feces, respectively. The majority of the remdesivir dose recovered in urine was GS‑441524 (49%), while 10% was recovered as remdesivir. These data indicate that renal clearance is the major elimination pathway for GS‑441524. The median terminal half-lives of remdesivir and GS‑441524 were approximately 1 and 27&nbsp;hours, respectively.</p><p>&nbsp;</p><p><u>Other special populations</u></p><p><em>Gender, race and age</em></p><p>Pharmacokinetic differences for gender, race, and age have not been evaluated.</p><p><em>Paediatric patients</em></p><p>Population pharmacokinetic models for remdesivir and its circulating metabolites (GS-704277 and GS-441524), developed using pooled data from studies in healthy subjects and in adult and paediatric patients with COVID-19, were used to predict pharmacokinetic exposures in 50&nbsp;paediatric patients aged &ge;&nbsp;28&nbsp;days to &lt;&nbsp;18&nbsp;years and weighing &ge;&nbsp;3&nbsp;kg (Study GS-US-540-5823) (Table 8). Geometric mean exposures (AUC<sub>tau</sub>, C<sub>max</sub> and C<sub>tau</sub>) for these patients at the doses administered were higher for remdesivir (44% to 147%), GS-441524 (-21% to 25%), and GS-704277 (7% to 91%) as compared to those in adult hospitalised patients with COVID-19. The increases were not considered clinically significant.</p><p><strong>Table&nbsp;8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic Parameters<sup>a</sup> Estimate of Steady-State Plasma Remdesivir, GS‑441524 and GS-704277 in Paediatric and Adult Hospitalised COVID-19 Patients</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td rowspan="3" style="vertical-align:top"><p><strong>Parameters</strong></p><p><strong>Mean<sup>b</sup> </strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Paediatric patients</strong></p></td><td style="vertical-align:top"><p><strong>Adult hospitalised patients (N=277)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cohort 1</strong></p></td><td style="vertical-align:top"><p><strong>Cohort 8</strong></p></td><td style="vertical-align:top"><p><strong>Cohort 2</strong></p></td><td style="vertical-align:top"><p><strong>Cohort 3</strong></p></td><td style="vertical-align:top"><p><strong>Cohort 4</strong></p></td><td rowspan="2">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>12 to &lt;18 Years and Weighing &ge;40&nbsp;kg (N=12)</strong></p></td><td style="vertical-align:top"><p><strong>&lt;12 Years and Weighing &ge;40&nbsp;kg (N=5)</strong></p></td><td style="vertical-align:top"><p><strong>28 Days to &lt;18 Years and Weighing 20 to &lt;40&nbsp;kg (N=12)</strong></p></td><td style="vertical-align:top"><p><strong>28 Days to &lt;18 Years and Weighing 12 to &lt;20&nbsp;kg (N=11)</strong></p></td><td style="vertical-align:top"><p><strong>28 Days to &lt;18 Years and Weighing 3 to &lt;12&nbsp;kg (N=10)</strong></p></td></tr></thead><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Remdesivir</strong></p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (ng/mL)</p></td><td style="vertical-align:top"><p>3910</p></td><td style="vertical-align:top"><p>3920</p></td><td style="vertical-align:top"><p>5680</p></td><td style="vertical-align:top"><p>5530</p></td><td style="vertical-align:top"><p>4900</p></td><td style="vertical-align:top"><p>2650</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>tau</sub> (h&bull;ng/mL)</p></td><td style="vertical-align:top"><p>2470</p></td><td style="vertical-align:top"><p>2280</p></td><td style="vertical-align:top"><p>3500</p></td><td style="vertical-align:top"><p>3910</p></td><td style="vertical-align:top"><p>2930</p></td><td style="vertical-align:top"><p>1590</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>GS-441524</strong></p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (ng/mL)</p></td><td style="vertical-align:top"><p>197</p></td><td style="vertical-align:top"><p>162</p></td><td style="vertical-align:top"><p>181</p></td><td style="vertical-align:top"><p>158</p></td><td style="vertical-align:top"><p>202</p></td><td style="vertical-align:top"><p>170</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>tau</sub> (h&bull;ng/mL)</p></td><td style="vertical-align:top"><p>3460</p></td><td style="vertical-align:top"><p>2640</p></td><td style="vertical-align:top"><p>2870</p></td><td style="vertical-align:top"><p>2400</p></td><td style="vertical-align:top"><p>2770</p></td><td style="vertical-align:top"><p>3060</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>tau</sub> (ng/mL)</p></td><td style="vertical-align:top"><p>98.3</p></td><td style="vertical-align:top"><p>76.2</p></td><td style="vertical-align:top"><p>73.8</p></td><td style="vertical-align:top"><p>69.4</p></td><td style="vertical-align:top"><p>78.4</p></td><td style="vertical-align:top"><p>78.4</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>GS-704277</strong></p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (ng/mL)</p></td><td style="vertical-align:top"><p>307</p></td><td style="vertical-align:top"><p>278</p></td><td style="vertical-align:top"><p>423</p></td><td style="vertical-align:top"><p>444</p></td><td style="vertical-align:top"><p>390</p></td><td style="vertical-align:top"><p>233</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>tau</sub> (h&bull;ng/mL)</p></td><td style="vertical-align:top"><p>815</p></td><td style="vertical-align:top"><p>537</p></td><td style="vertical-align:top"><p>754</p></td><td style="vertical-align:top"><p>734</p></td><td style="vertical-align:top"><p>691</p></td><td style="vertical-align:top"><p>501</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp; PK parameters were simulated using PopPK modeling with 0.5 hour of duration for remdesivir infusions.</p><p>b&nbsp;&nbsp;&nbsp; Geometric mean estimates.</p><p>Paediatric hospitalised patients are from Study GS‑US‑540‑5823; patients received 200&nbsp;mg on Day 1 followed by remdesivir 100&nbsp;mg once daily on subsequent days (Cohort 1 and 8), or 5&nbsp;mg/kg on Day 1 followed by remdesivir 2.5&nbsp;mg/kg once daily on subsequent days (Cohort 2-4) for a total treatment duration of up to 10 days.</p><p>Adult hospitalised patients are from Study CO‑US‑540‑5844 (a phase 3 randomised study to evaluate the safety and antiviral activity of remdesivir in patients with severe COVID-19); patients received 200&nbsp;mg on Day 1 followed by remdesivir 100&nbsp;mg once daily on subsequent days (10 days total treatment duration).</p><p><em>Renal impairment</em></p><p>The pharmacokinetics of remdesivir and GS‑441524 in renal impairment have not been evaluated. Remdesivir is not cleared unchanged in urine to any substantial extent, but its main metabolite GS‑441524 is renally cleared and the metabolite levels in plasma may theoretically increase in patients with impaired renal function. The excipient betadex sulfobutyl ether sodium is renally cleared and accumulates in patients with decreased renal function. Veklury should not be used in patients with eGFR &lt;30&nbsp;mL/min.</p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of remdesivir and GS‑441524 in hepatic impairment have not been evaluated. The role of the liver in the metabolism of remdesivir is unknown.</p><p><em>Interactions</em></p><p>The potential of interaction of remdesivir as a victim was not studied with regards to the inhibition of the hydrolytic pathway (esterase). The risk of clinically relevant interaction is unknown.</p><p>&nbsp;</p><p>Remdesivir inhibited CYP3A4 <em>in&nbsp;vitro </em>(see section&nbsp;4.5). At physiologically relevant concentrations (steady-state), remdesivir or its metabolites GS‑441524 and GS‑704277 did not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 <em>in&nbsp;vitro. </em>Remdesivir may however transiently inhibit CYP2B6, 2C8, 2C9 and 2D6 on the first day of administration. The clinical relevance of this inhibition was not studied. The potential for time-dependent inhibition of CYP450 enzymes by remdesivir was not studied.</p><p>Remdesivir induced CYP1A2 and potentially CYP3A4, but not CYP2B6 <em>in vitro </em>(see section&nbsp;4.5).</p><p><em>In&nbsp;vitro </em>data indicates no clinically relevant inhibition of UGT1A1, 1A3, 1A4, 1A6, 1A9 or 2B7 by remdesivir or its metabolites GS‑441524 and GS‑704277.</p><p>Remdesivir inhibited OATP1B1 and OATP1B3 <em>in vitro</em> (see section&nbsp;4.5). No data is available for OAT1, OAT3 or OCT2 inhibition by remdesivir.</p><p>At physiologically relevant concentrations, remdesivir and its metabolites did not inhibit P-gp and BCRP <em>in&nbsp;vitro.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Toxicology</u></p><p>Following intravenous administration (slow bolus) of remdesivir to rhesus monkeys and rats, severe renal toxicity occurred after short treatment durations. In male rhesus monkeys at dosage levels of 5, 10, and 20&nbsp;mg/kg/day for 7&nbsp;days resulted, at all dose levels, in increased mean urea nitrogen and increased mean creatinine, renal tubular atrophy, and basophilia and casts, and an unscheduled death of one animal at the 20&nbsp;mg/kg/day dose level.In rats, dosage levels of &gt;3&nbsp;mg/kg/day for up to 4&nbsp;weeks resulted in findings indicative of kidney injury and/or dysfunction. Systemic exposures (AUC) of the predominant circulating metabolite of remdesivir (GS‑441524) were 0.1&nbsp;times (monkeys at 5&nbsp;mg/kg/day) and 0.3&nbsp;times (rats at 3&nbsp;mg/kg/day) the exposure in humans following intravenous administration at the recommended human dose (RHD).</p><p><em>Carcinogenesis</em></p><p>Long-term animal studies to evaluate the carcinogenic potential of remdesivir have not been performed.</p><p><em>Mutagenesis</em></p><p>Remdesivir was not genotoxic in a battery of assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes, and <em>in&nbsp;vivo</em> rat micronucleus assays.</p><p><em>Reproductive toxicity</em></p><p>In female rats, decreases in corpora lutea, numbers of implantation sites, and viable embryos, were seen when remdesivir was administered intravenously daily at a systemically toxic dose (10&nbsp;mg/kg/day) 14&nbsp;days prior to mating and during conception; exposures of the predominant circulating metabolite (GS‑441524) were 1.3&nbsp;times the exposure in humans at the RHD. There were no effects on female reproductive performance (mating, fertility, and conception) at this dose level.</p><p>&nbsp;</p><p>In rats and rabbits, remdesivir demonstrated no adverse effect on embryofoetal development when administered to pregnant animals at systemic exposures (AUC) of the predominant circulating metabolite of remdesivir (GS‑441524) that were up to 4 times the exposure in humans at the RHD.</p><p>&nbsp;</p><p>In rats, there were no adverse effects on pre- and post-natal development at systemic exposures (AUC) of the predominant circulating metabolite of remdesivir (GS‑441524) that were similar to the exposure in humans at the RHD.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Betadex sulfobutyl ether sodium</p><p>Hydrochloric acid (to adjust pH)</p><p>Sodium hydroxide (to adjust pH)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed or administered simultaneously with other medicinal products in the same dedicated line except those mentioned in section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials
3 years

Reconstituted and diluted solution for infusion
Store diluted remdesivir solution for infusion up to 24 hours at room temperature (20° to 25°C) or 48 hours in a refrigerator (2°C – 8°C).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type&nbsp;I clear glass vial, an elastomeric closure, and an aluminium overseal with a flip-off cap.</p><p>Pack size: 1 vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prepare solution for infusion under aseptic conditions and on the same day as administration. Remdesivir should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Should either be observed, the solution should be discarded and fresh solution prepared.</p><p>Remdesivir must be reconstituted with 19&nbsp;mL sterile water for injections and diluted in sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection before being administered via intravenous infusion over 30 to 120&nbsp;minutes.</p><p>&nbsp;</p><p>Preparation of remdesivir solution for infusion</p><p><em>Reconstitution</em></p><p>Remove the required number of single-use vial(s) from storage. For each vial:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aseptically reconstitute remdesivir powder for concentrate for solution for infusion by addition of 19&nbsp;mL of sterile water for injections using a suitably sized syringe and needle per vial.</p><p>◦&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discard the vial if a vacuum does not pull the sterile water for injections into the vial.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only use <strong>sterile water</strong> for injection to reconstitute remdesivir powder.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immediately shake the vial for 30&nbsp;seconds.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allow the contents of the vial to settle for 2 to 3&nbsp;minutes. A clear solution should result.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the contents of the vial are not completely dissolved, shake the vial again for 30&nbsp;seconds and allow the contents to settle for 2 to 3&nbsp;minutes. Repeat this procedure as necessary until the contents of the vial are completely dissolved.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inspect the vial to ensure the container closure is free from defects and the solution is free of particulate matter.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dilute immediately after reconstitution.</p><p><em>Dilution</em></p><p>Care should be taken to prevent inadvertent microbial contamination. As there is no preservative or bacteriostatic agent present in this product, aseptic technique must be used in preparation of the final parenteral solution. It is recommended to administer immediately after preparation when possible.</p><p><em>Adults and paediatric patients (weighing at least 40&nbsp;kg)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Using Table&nbsp;9, determine the volume of sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection to withdraw from the infusion bag.</p><p><strong>Table&nbsp;9:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended dilution instructions&nbsp;&ndash; Reconstituted remdesivir powder for concentrate for solution for infusion</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:bottom"><p>Remdesivir dose</p></td><td style="vertical-align:bottom"><p><strong>Sodium chloride 9&nbsp;mg/mL (0.9%) infusion bag volume to be used</strong></p></td><td style="vertical-align:bottom"><p><strong>Volume to be withdrawn and discarded from sodium chloride 9&nbsp;mg/mL (0.9%) infusion bag</strong></p></td><td style="vertical-align:bottom"><p>Required volume of reconstituted remdesivir</p></td></tr></thead><tbody><tr><td rowspan="2"><p>200&nbsp;mg (2&nbsp;vials)</p></td><td><p>250&nbsp;mL</p></td><td><p>40&nbsp;mL</p></td><td><p>2&nbsp;&times; 20&nbsp;mL</p></td></tr><tr><td><p>100&nbsp;mL</p></td><td><p>40&nbsp;mL</p></td><td><p>2&nbsp;&times; 20&nbsp;mL</p></td></tr><tr><td rowspan="2"><p>100&nbsp;mg (1&nbsp;vial)</p></td><td><p>250&nbsp;mL</p></td><td><p>20&nbsp;mL</p></td><td><p>20&nbsp;mL</p></td></tr><tr><td><p>100&nbsp;mL</p></td><td><p>20&nbsp;mL</p></td><td><p>20&nbsp;mL</p></td></tr></tbody></table><p>NOTE: 100&nbsp;mL should be reserved for patients with severe fluid restriction, e.g. with ARDS or renal failure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw and discard the required volume of sodium chloride 9&nbsp;mg/mL from the bag using an appropriately sized syringe and needle per Table&nbsp;9.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the required volume of reconstituted remdesivir using an appropriately sized syringe per Table&nbsp;9. Discard any unused portion remaining in the remdesivir vial.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transfer the required volume of reconstituted remdesivir to the selected infusion bag.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently invert the bag 20&nbsp;times to mix the solution in the bag. Do not shake.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The prepared solution is stable for 24&nbsp;hours at room temperature (20&deg;C to 25&deg;C) or 48&nbsp;hours in the refrigerator (2&deg;C to 8&deg;C).</p><p><em>Paediatric patients (at least 4&nbsp;weeks of age and weighing 3&nbsp;kg to less than 40&nbsp;kg)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Further dilute the 100&nbsp;mg/20&nbsp;mL (5 mg/mL) remdesivir concentrate to a fixed concentration of 1.25&nbsp;mg/mL using 0.9% sodium chloride.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The total required infusion volume of the 1.25&nbsp;mg/mL remdesivir solution for infusion is calculated from the paediatric weight-based dosing regimens of 5&nbsp;mg/kg for the Loading Dose and 2.5&nbsp;mg/kg for each Maintenance Dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Small 0.9% sodium chloride infusion bags (e.g., 25, 50, or 100&nbsp;mL) or an appropriately sized syringe should be used for paediatric dosing. The recommended dose is administered via IV infusion in a total volume dependent on the dose to yield the target remdesivir concentration of 1.25&nbsp;mg/mL.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A syringe may be used for delivering volumes &lt;50&nbsp;mL.</p><p><span style="text-align:unset">After infusion is complete, flush with at least 30&nbsp;mL of sodium chloride 9&nbsp;mg/mL.</span></p><p><u>Disposal</u></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>